2021年临床试验更新:血友病治疗的创新
该综述概述了血友病新型疗法的活跃及近期完成的临床试验和临床前数据,涵盖工程化凝血因子浓缩物、替代疗法、再平衡疗法和基因转移/编辑等方向,旨在减少当前治疗负担并可能减少给药频率或静脉给药需求。
要点
- 新型血友病疗法包括工程化因子浓缩物、替代疗法、再平衡疗法和基因转移/编辑。
- 新兴治疗可能减少治疗频率或静脉给药需求,但可能给止血实验室评估带来新挑战。
- 再平衡凝血级联或引入新遗传物质在应激或炎症状态下存在潜在风险。
核心结论
- 多种新兴血友病疗法旨在减少当前治疗负担,但需确保不引入显著新健康风险并维持或改善结局。
研究设计与样本
- 综述性文章,聚焦活跃和近期完成的临床试验及新兴临床前数据。
主要发现
- 工程化因子浓缩物、替代疗法、再平衡疗法和基因转移/编辑是主导临床试验的血友病治疗方向。
- 新兴治疗选项可能减少治疗频率或静脉给药需求。
- 新兴治疗可能给止血实验室评估带来新挑战。
- 再平衡凝血级联在应激或炎症状态下的潜在后果及引入新遗传物质的风险并非微不足道。
临床怎么用
- 临床医生应了解新兴血友病疗法可能减少治疗频率或静脉给药需求,但需关注实验室评估挑战和潜在风险。
局限性
- 本文为综述,未报告具体研究样本量、阈值或统计值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapies engineered to prolong clotting factor protein circulation time, manipulate the balance of pro-coagulant and anti-coagulant proteins, or introduce new genetic material to enable endogenous factor protein production dominate the clinical trial landscape of hemophilia. The availability of clotting factor concentrates and the establishment of primary prophylaxis have dramatically improved health outcomes for hemophilia patients. But, the burden of hemostatic therapy remains significant, and many barriers to consistent longitudinal use of prophylaxis exist. Several types of emerging therapeutics including engineered factor concentrates, substitutive therapies, rebalancing therapies, and gene transfer/editing all aim to reduce the challenges of current hemophilia treatment. Emerging treatment options may reduce treatment frequency or need for intravenous administration. They may also introduce new challenges in laboratory assessment of hemostasis. These novel therapies must not introduce significant new health risks and continue to support similar or improved outcomes. The potential ramifications of rebalancing the coagulation cascade, particularly in a stress or inflammatory state, or introduction of new genetic material are not trivial. The focus of this review is to provide an overview of active and recently completed clinical trials as well as emerging preclinical data investigating new therapeutic possibilities for hemophilia patients and potentially other rare bleeding disorders.
引用
- Croteau SE, Wang M, Wheeler AP, et al. 2021 clinical trials update: Innovations in hemophilia therapy. Am J Hematol. 2020. PMID: 33064330. doi:10.1002/ajh.26018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。